Cargando…
Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A retrospective cohort study
PURPOSE: Treatment options for urinary tract infection (UTI) caused by extended-spectrum beta-lactamase (ESBL)-producing organisms are limited other than carbapenem. Accordingly, clinicians should investigate alternative antimicrobial options for limited infection. This study was performed to assess...
Autores principales: | Ahn, Sun Tae, Han, Da Eun, Lee, Dong Hyun, Kim, Jong Wook, Park, Hong Seok, Moon, Du Geon, Oh, Mi Mi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100019/ https://www.ncbi.nlm.nih.gov/pubmed/33943052 http://dx.doi.org/10.4111/icu.20200240 |
Ejemplares similares
-
Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli
por: Al-Tamimi, Mohammad, et al.
Publicado: (2022) -
Oral Amoxicillin-Clavulanic Acid Treatment in Urinary Tract Infections Caused by Extended-Spectrum Beta-Lactamase–Producing Organisms
por: Beytur, Ali, et al.
Publicado: (2014) -
Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli
por: Cho, Sung-Yeon, et al.
Publicado: (2016) -
Increased Amoxicillin–Clavulanic Acid Resistance in Escherichia coli Blood Isolates, Spain
por: Oteo, Jesús, et al.
Publicado: (2008) -
Reconciling the Potentially Irreconcilable? Genotypic and Phenotypic Amoxicillin-Clavulanate Resistance in Escherichia coli
por: Davies, Timothy J., et al.
Publicado: (2020)